MedTrace Logo

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE

NCT01291667 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 330

Last updated 2011-02-08

No results posted yet for this study

Summary

Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China. Trastuzumab has been proved valuable treatment for HER2-positive breast cancer patients. Cipterbin® is developing by Shanghai CP Guojian Pharmaceutical Co.Ltd.Now we carried on the phase III trial in order to prove Cipterbin® 's efficacy and safety.

Conditions

  • Progress-free Survival
  • Overall Response Rate
  • Adverse Events

Sponsors & Collaborators

  • Shanghai CP Guojian Pharmaceutical Co., Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01291667 on ClinicalTrials.gov